## EW: Edwards Lifesciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.7% below STRENGTH zone (4.0-10.0%); PEG 4.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($82.33)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Ninety One UK Ltd Buys 969,030 Shares of Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20260101T140905 | Bullish | Relevance: 100%
- Ninety One UK Ltd has significantly increased its stake in Edwards Lifesciences Corporation by purchasing an additional 969,030 shares, bringing its total holdings to 7,908,572 shares, valued at approximately $615.1 million. This makes Edwards Lifesciences the 20th largest holding for Ninety One UK Ltd, representing about 1.4% of its total portfolio. The medical research company recently exceeded Q3 earnings estimates with EPS of $0.67 and revenue of $1.55 billion, while analysts maintain a "Moderate Buy" rating with a target price of $93.95.

**2. Ninety One North America Inc. Acquires 71,017 Shares of Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20260101T134448 | Somewhat-Bullish | Relevance: 100%
- Ninety One North America Inc. increased its stake in Edwards Lifesciences Corporation by 14.8%, acquiring an additional 71,017 shares, raising its total holdings to 551,399 shares valued at approximately $42.88 million. This makes Edwards Lifesciences the 19th largest position in Ninety One's portfolio, representing about 2.0% of its holdings. The article also notes recent insider selling by executives CFO Scott B. Ullem and VP Donald E. Bobo, Jr., totaling 45,465 shares worth approximately $3.8 million.

**3. Cwm LLC Purchases 43,065 Shares of Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251231T094751 | Somewhat-Bullish | Relevance: 100%
- Cwm LLC increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 105.4% in the third quarter, acquiring an additional 43,065 shares to own a total of 83,916 shares valued at $6,526,000. Several other hedge funds also adjusted their holdings in EW. Wall Street analysts maintain a "Moderate Buy" consensus rating with a target price of $93.95 for Edwards Lifesciences.

**4. Analysts Are Bullish on These Healthcare Stocks: Natera (NTRA), Immunome (IMNM)**
- Source: The Globe and Mail | 20251231T031000 | Somewhat-Bullish | Relevance: 81%
- Analysts from TD Cowen and Citi have issued bullish ratings for several healthcare stocks. Natera (NTRA) received a Strong Buy consensus with a 5.1% upside, while Immunome (IMNM) also has a Strong Buy consensus with a significant 50.8% upside. Edwards Lifesciences (EW) maintained a Moderate Buy rating with a 10.9% upside.

**5. Barclays Keeps Their Hold Rating on Johnson & Johnson (JNJ)**
- Source: The Globe and Mail | 20251231T080819 | Neutral | Relevance: 64%
- Barclays analyst Matt Miksic reiterated a Hold rating on Johnson & Johnson (JNJ) with a $217.00 price target. This comes as the company reported strong Q3 revenues of $23.99 billion and a net profit of $5.15 billion, exceeding last year's figures. Insider sentiment is neutral, though one director recently purchased 1,250 shares.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 11, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $100 | $90 | +11% |
| 2025-12-17 | Canaccord Genui | $87 | $89 | -2% |
| 2025-12-16 | Baird | $87 | $88 | -1% |
| 2025-12-11 | Citigroup | $101 | $96 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | up | Overweight |
| 2025-12-17 | Canaccord Genui | main | Hold |
| 2025-12-16 | Baird | main | Neutral |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 12 ($3.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. Valuation stretched: PEG 4.9x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 11 raises (avg +5%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.86 signals overvaluation risk, limited margin of safety. Forward P/E 29.7x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $50.1B |
| Beta | 0.97 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.86 |
| Forward P/E | 29.7 |
| Current P/E | 33.0 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 0.7% (minimal 5-day change). Below STRENGTH zone by 3.3pp (needs >4.0% for momentum thesis). MRS_5 (-0.2%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 52. OFD pattern: -DLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.70% (CS: 49) | Neutral |
| RSI_14 | 51.5 | Neutral |
| MACD Histogram | -0.08 | Bearish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.013x | Above |
| vs SMA200 | 1.094x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $85.33
- **Stop Loss:** $82.33 (3.5% risk)
- **Target:** $88.33 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 480
- **Position Value:** $40,958.40
- **Portfolio %:** 40.96%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*